Video
Dr. Kim Discusses the Primary Efficacy Results From the B-F1RST Trial in NSCLC
Author(s):
Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the primary efficacy results from the B-F1RST trial in non–small cell lung cancer (NSCLC).
Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the primary efficacy results from the B-F1RST trial in non—small cell lung cancer (NSCLC).
B-F1RST is a single-arm trial assessing a novel blood-based tumor mutational burden (TMB) marker in patients with NSCLC who are receiving single-agent atezolizumab (Tecentriq) in the frontline setting. TMB is an important and emerging area in the use of checkpoint inhibitor therapy, Kim says. PD-L1 is used as a biomarker for checkpoint inhibitor therapy right now, and while it has clinical utility, many feel that there is room for more biomarkers. A blood-based TMB marker was explored in this trial.
Patients were treated with atezolizumab until progression or lack of clinical benefit. TMB was assessed at baseline. The blood that was submitted had to have a minimum amount of tumor cell content in order for those patients to be evaluated, Kim explains.
